	US 11,873,347 B2
	Antigen-binding chimeric proteins and methods and uses thereof
Jan Steyaert, Beersel (BE); Els Pardon, Wezemaal (BE); Tomasz Uchanski, Libramont-Chevigny (BE); and Wim Vranken, Brussels (BE)
Assigned to VIB VZW, Ghent (BE); and VRIJ UNIVERSITEIT BRUSSEL, Brussels (BE)
Appl. No. 16/760,394
Filed by VIB VZW, Ghent (BE); and VRIJE UNIVERSITEIT BRUSSEL, Brussels (BE)
PCT Filed Oct. 31, 2018, PCT No. PCT/EP2018/079891 § 371(c)(1), (2) Date Apr. 29, 2020, PCT Pub. No. WO2019/086548, PCT Pub. Date May 9, 2019.
Claims priority of application No. 17199472 (EP), filed on Oct. 31, 2017; and application No. 18199709 (EP), filed on Oct. 10, 2018.
Prior Publication US 2021/0206880 A1, Jul. 8, 2021
Int. Cl. C07K 16/46 (2006.01); C07K 14/195 (2006.01); G01N 23/20 (2018.01); G01N 33/68 (2006.01); C07K 14/705 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01)

CPC C07K 16/465 (2013.01) [C07K 14/005 (2013.01); C07K 14/195 (2013.01); C07K 14/705 (2013.01); C12N 7/00 (2013.01); G01N 23/20 (2013.01); G01N 33/6845 (2013.01); C07K 2299/00 (2013.01); C07K 2317/569 (2013.01); C07K 2319/03 (2013.01); C12N 2795/00022 (2013.01); C12N 2795/00023 (2013.01)]

22 Claims

1. An antigen-binding chimeric protein comprising an antigen-binding domain of an immunoglobulin fused with a scaffold protein, wherein the scaffold protein interrupts the primary topology of the antigen-binding domain at one or more exposed regions comprising a loop or β-turn of the antigen-binding domain, wherein said one or more exposed regions are not in complementarity-determining regions, wherein the antigen-binding domain retains the antigen-binding capacity, and wherein the scaffold protein is fused to the antigen-binding domain via at least two direct fusions or fusions made by a linker.